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Background: Patient-centered care has been proposed as a strategy for improving treatment 
outcomes in the management of psoriasis and other chronic diseases. A more detailed under-
standing of patients’ utilities and disutilities associated with treatment features may facilitate 
shared decision-making in the clinical encounter. The purpose of this study was to examine 
the features of psoriasis treatment that are most and least preferred by patients and to identify 
correlates of these preferences.
Methods: A cross-sectional survey of 163 patients with moderate-to-severe psoriasis was 
conducted in a German academic medical center. We assessed patients’ characteristics, elicited 
their preferences for a range of potential treatment features, and quantified preference scores 
(utilities) associated with each treatment feature using hierarchical Bayes estimation. After 
identifying the most and least preferred treatment features, we explored correlates of these 
preferences using multivariate regression models.
Results: Mean preference scores (MPS) for the least preferred treatment features were 
  consistently greater than those for the most preferred treatment features. Patients generally 
expressed strong preferences against prolonged treatments in the inpatient setting (MPS = –13.48) 
and those with a lower probability of benefit (MPS = −12.28), while treatments with a high 
probability of benefit (MPS = 10.51) were generally preferred. Younger patients and women 
were more concerned with treatment benefit as compared with older patients and men.
Conclusion: Both negative and positive preferences appear important for shared 
  decision-making. Recognition of characteristics associated with strong negative preferences 
may be particularly useful in promoting patient-centered environments.
Keywords: conjoint analysis, patient preferences, treatment preferences, psoriasis
Introduction
Psoriasis is a common skin disease with substantial impact on those afflicted.1,2 
The disease burden and social stigma associated with psoriasis significantly affect 
  physical and psychological well-being.1–3 Because there is no cure for psoriasis, disease 
management aims at reducing disease severity and improving overall health-related 
quality of life.4,5
Several forms of effective treatment have been developed for management of 
psoriasis.4,6 However, despite the availability of a wide range of options, treatment 
nonadherence is high.7 Shared decision-making, a central component of patient-
centered care, is a strategy that promotes involvement of patients in the manage-
ment of their disease, in part to enhance adherence.8 Shared decision-making may 
involve eliciting patients’ preferences and the active use of preferences in treatment 
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  decision-making.8,9 As a result, a more detailed understanding 
by physicians of the treatment preferences of patients with 
psoriasis within the framework of shared decision-making 
has been advocated.10
Previous studies have demonstrated that patients with 
psoriasis have distinct preferences for many aspects of the 
treatment process,11 including treatment location, mode of 
delivery,12 probability of treatment benefit,13 and   frequency.14 
Much of this work has focused almost exclusively on   positive 
preferences or the utility of a given treatment choice. However, 
this approach tends to ignore the rationality of decision-making 
in which individuals weigh possible gains against the possible 
losses (or the disutility) associated with a given choice.15
To promote shared decision-making in the management 
of psoriasis, it may be useful to characterize better patients’ 
preferences for treatment features they desire and those they 
wish to avoid. Further, identifying factors associated with 
patient utilities and disutilities may inform the development 
of more effective treatment strategies. The aim of this study 
was to examine features of psoriasis treatment that are most 




Patients were recruited from the outpatient psoriasis   clinics 
in the Department of Dermatology, University Medical 
Centre Mannheim, Heidelberg University. Selection was 
based on criteria that ensured participants could potentially 
be offered a wide range of currently available psoriasis 
  treatments. Specifically, patients were eligible for the study 
if they were at least 18 years of age, had physician-diagnosed 
psoriasis that was moderate or severe according to the   criteria 
of the Committee for Medicinal Products for Human Use16 
(ie, Psoriasis Area and Severity Index .10 and/or had 
involvement of the head, and palmar and plantar surfaces), 
or had psoriatic arthritis with skin involvement according to 
Classification of Psoriatic Arthritis criteria.17 Patients with 
psoriatic arthritis, but no skin involvement, and those unable 
to complete an online survey independently were excluded. 
Informed consent was obtained prior to study participation. 
The study followed the tenets of the Helsinki Declaration 
and was approved by the ethics committee of the Medical 
Faculty Mannheim, Heidelberg University.
Data collection and data elements
Patients completed a self-administered online   survey 
before their medical appointment. The survey involved 
assessment of patient preferences for psoriasis   treatment 
using a   choice-based conjoint analysis exercise.18 
Patients’   characteristics and other potential confounders 
of patients’ preferences were also assessed by the online 
survey and included gender, age in years, marital status 
(single, couples living together, divorced, widowed), 
employment status (employed/unemployed), highest level 
of   educational attainment based on categories used by the 
German Federal Statistics Office (#11 years of school-
ing = low, 12–15 years = medium, .15 years = high),8 net 
monthly household income (, 1500,  1500–3000, .
3000), disease duration in years,19–21 smoking status (still 
smoking, previous smoker, never smoked),21 current thera-
pies (topical, light, tablets, injection, infusion) and known 
  comorbidities associated with psoriasis (psoriatic arthritis, 
diabetes,   cardiovascular disease, depression).20,22,23
The conjoint analysis exercise has been described in 
detail elsewhere.12,24 In summary, it involves five main 
stages:   identifying treatment attributes for the study; 
  determining levels (categories) for each attribute; pre-
senting   hypothetical scenarios consisting of different 
attribute levels; obtaining participant preferences for each 
scenario; and data analysis.18,25 In specifying the treat-
ment attributes for   psoriasis, we first identified a range of 
potentially appropriate and available treatment options by 
reviewing the German Evidence-based Guidelines for the 
Treatment of Psoriasis. Consultations with dermatologists 
confirmed and, in some cases, augmented our selection. 
We then decomposed the treatment list into attributes and 
attribute levels. Four attribute levels for each treatment 
attribute were specified to limit respondent burden (see 
Table 1).12
Survey design
A survey containing items related to the conjoint analysis was 
designed for online administration using Sawtooth software 
(Sawtooth Inc, Sequim, WA). The survey comprised two 
parts to enable distinctions between patient preferences for 
treatment processes (eg, location of treatment) and those for 
possible treatment outcomes or consequences (eg, possibility 
of side effects). Patients were presented with 12 pair-wise 
comparisons of randomly selected hypothetical treatment 
scenarios (for an example, see Schaarschmidt et al12).
Data analysis
Conventionally, latent class analysis is used for segmentation 
of conjoint analysis samples into subgroups of respondents 
for each treatment attribute, resulting in relative importance 
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scores for each attribute.26 However, because we were 
  specifically interested in looking at the most and least pre-
ferred levels within each treatment attribute, and not relative 
attribute importance, individual-level preference (utility) 
scores for treatment attribute levels were estimated using 
hierarchical Bayes estimation.18 Mean preference scores for 
each attribute level were calculated using data from the entire 
sample and were rank-ordered from most to least preferred. 
Independent associations of patient characteristics and other 
potential correlates of patients’ preferences with the prefer-
ence scores for the most preferred and least preferred pso-
riasis treatment attribute levels (as dependent variables) were 
evaluated using six separate multivariate linear regression 
models. Three models were developed for the most preferred 
attribute levels (ie, those with the highest utility scores) and 
three models for the three least preferred attribute levels. 
Statistical analyses were performed using either Sawtooth 
software or SPSS (v 19; SPSS Inc, Chicago, IL). We used an 
alpha value of 0.05 to indicate statistical significance. Given 
the exploratory nature of this analysis, we did not adjust the 
alpha value for the multiple testing implicit in the models 
we generated.
Results
Of the 163 participants recruited, 67 (41.1%) were women, and 
the mean age was 49.3 (range 18–80) years. The mean number 
of years since diagnosis (ie, disease duration) was 18 (range 
1–75) years. Participants who reported that they were working 
represented 58.9% of the study sample (see Table 2).
Mean preferences for attribte levels
Utility scores for the most and least preferred attribute levels 
are shown in Figure 1. The greater the importance of the 
Table 1 Profile of treatment attributes and attribute levels used in conjoint analysis exercises
Treatment attributes Level 1 Level 2 Level 3 Level 4
Treatment duration 5 minutes 15 to 30 minutes 1 hour 2 hours
Treatment frequency Once every 3 months Once every 2 weeks Two times each week Twice daily
Treatment cost €0 per month €50 per month €100 per month €200 per month
Treatment location At home At home and follow-up  
at local doctor’s
Outpatient clinic Hospital for  
3 weeks
Treatment delivery method Topical Tablets Injection/intravenous infusion Light therapy
Magnitude of beneficial effects 100% reduction 75% reduction 50% reduction 25% reduction
Duration of beneficial effects 1 year or more 6–8 months 3–5 months 2 weeks
Probability of side effects 100% 50% 10% 1%
Probability of beneficial effects 100% 80% 60% 40%
reversibility of side effects 100% 80% 60% 40%




Temporary, moderate side 
effects more than skin
Severe side 
effects more  
than skin
  attribute levels to the patients, the higher the mean utility 
score. A positive sign (+) indicates positive utility and a nega-
tive sign (−) indicates a converse relationship, or disutility.
In nearly every instance, the magnitude of the mean 
preference score for the least preferred attribute level 
exceeded that for its most preferred level. The lowest rank-
ordered attribute levels, ie, those that were least preferred, 
included hospital stay for 3 weeks (−13.48), lower (40%) 
probability of benefit (−12.28), and lower (25%) expected 
magnitude of benefit (−10.86). Patients expressed a strongly 
negative preference for a treatment in which side effects were 
highly likely (−7.77) compared with treatments for which 
side effects may be severe (−3.23). Conversely, patients 
expressed strong positive preferences for a treatment with the 
highest (100%) probability of benefit (+10.51), followed by 
the possibility of achieving significant reduction of psoriasis 
plaques (+9.17). Other relatively strongly positive prefer-
ences were expressed for treatments with a lower probability 
of side effects (+7.08), no costs (+5.57), and treatments that 
could be administered at home (+4.23).
Correlates of patient preferences  
for most and least preferred  
attribute levels
We observed correlates between patient or treatment character-
istics and six of the treatment attribute levels for which patients 
expressed the strongest positive and negative preferences (see 
Table 3). For example, younger patients and women were 
more concerned with treatment benefit than men and older 
patients. Singles, divorced, widowed, and subjects separated 
from their partners preferred treatments with a high probability 
of benefit and treatments expected to have a high magnitude 
of benefit, and least preferred treatments with a lower magni-
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Table 2 Sample characteristics
Characteristics (n = 163)
Gender
  Women 67 (41.1%)
  Age (years), mean ± SD (range) 49.3 ± 14.1 (18–80)
Marital status
  Single 38 (23.3%)
  Couple 99 (60.7%)
  Divorced, widowed, separated 26 (16.0%)
Education
 # 11 years 29 (17.8%)
  12–15 years 97 (59.5%)
 . 15 years 37 (22.7%)
Monthly household income (in euros)
  , €1500 55 (33.7%)
  €1500–3000 73 (44.8%)
 . €3000 35 (21.5%)
Employment status
  Working 96 (58.9%)
  Not working 67 (41.1%)
  Disease duration (years), mean ± SD (range) 18.0 ± 13.9 (1–75)
  Currently receiving psoriasis therapy 153 (93.9%)
Current therapy
  Topical 61 (37.4%)
  Light 24 (14.7%)
  Tablets 46 (28.2%)
  Injection 28 (17.2%)
  Infusion 8 (4.9%)
Comorbidities
  Psoriatic arthritis 44 (27.0%)
  Diabetes 13 (8.0%)
  Cardiovascular 23 (13.5%)
  Depression 21 (12.9%)
Smoking status
  Still smoking 61 (37.4%)
  Smoked before 59 (36.2%)
  Never smoked 43 (26.4%)
Abbreviation: SD, standard deviation.
tude of beneficial effects, as compared with those who were 
married or living with a partner. Treatment at the hospital for 
3 weeks appeared to be less preferred by singles as compared 
with couples (ie, those married or living with a partner) and 
by patients with higher educational attainment (more than 
15 years of schooling) as compared with those with lower 
educational attainment (#11 years of schooling).
A low probability of side effects was most preferred 
by older patients as compared with younger patients, by 
patients with more than 15 years of schooling as compared 
with those with #11 years of schooling, and by patients 
receiving light therapy as compared with those receiving 
other therapies. Patients with lower educational attainment 
(#11 years of schooling) appeared to be most concerned 
about treatment benefits. Patients receiving injections or 
topical treatments appeared to prefer treatment with a high 
probability of    benefit. However, patients receiving injections 
least preferred treatments expected to have a lower probabil-
ity of benefit, while those receiving topical treatments least 
preferred treatment at the hospital for 3 weeks. The results 
also showed that depressed patients were less concerned 
with the expected magnitude of beneficial effects. Patients 
still smoking appeared to be more concerned with the prob-
ability of  benefit and the reduction in psoriasis plaques as 
compared with those who were not current smokers (ie, those 
who had smoked before and quit or who had never smoked).
Discussion
The purpose of this study was to expand on the patient prefer-
ence literature for individuals with psoriasis by examining 
preferences for levels within psoriasis treatment attributes. 
We demonstrated not only the utility of receiving a preferred 
treatment, but also the disutility associated with receiving 
a nonpreferred treatment. Moreover, we identified several 
correlates of patient preferences for treatment attributes that 
were most and least preferred.
We observed that the magnitude of the mean preference 
scores for least preferred attribute levels was consistently 
higher than the magnitude of the mean scores for the most 
preferred attribute levels. Our results suggest that patients are 
not only concerned about receiving preferred treatments, but 
perhaps are more concerned that treatments associated with 
strong disutility not be recommended.27 Evidence from the 
psychology literature reveals a negativity bias,   specifically 
that many are affected to a greater extent by bad things 
  happening to them rather than good events. As a result, 
individuals may be more motivated to avoid bad things than 
to pursue good things.15 Moreover, previous work suggests 
that the saliency of bad events or negative emotions lasts 
longer than good events or positive emotions.28,29 Taken 
together, these prior findings may explain the magnitude of 
the   negative utility that participants in our study assigned to 
the least preferred treatment attribute levels. Based on our 
results, it is possible that failure to acknowledge negative 
preferences in treatment decision-making, ie, recommending 
treatments associated with strong disutility, may affect patient 
satisfaction and adherence with recommended   treatment to 
a greater degree than recommendation of treatments with 
attributes that are only weakly preferred.
For example, the strongly negative utilities identified 
through the conjoint analysis in our study suggest that 
  participants were more concerned about improvement of 
their skin condition than about the reversibility or the severity 
of treatment side effects. Studies exploring the significance 
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Figure 1 Mean preference scores of the most and least preferred attribute levels.
of treatment side effects and treatment benefit in chronic 
disease management have reported mixed results.11 In some 
studies, patients valued the risk and the severity of treat-
ment side effects over treatment benefit,11,30 while in others 
patients were reported to be willing to accept the risks of 
treatment if benefits were perceived to be high.12,31 These 
contradictory findings may have resulted from the way in 
which the severity of side effects was explicitly defined or 
presented (eg, “risk of liver damage or skin cancer” versus 
“side effects involving more than the skin”). In cases where 
the severity of side effects was defined, treatment side effects 
became the most important determinant of patient treatment 
preferences.11 When eliciting patient preferences, explicitly 
defining treatment attributes has both advantages and dis-
advantages. For example, use of explicit language (eg, “risk 
of liver damage or skin cancer”) may result in dominant 
preferences in which respondents become unwilling to trade 
between attributes.32 However, using explicit language has 
the advantage of being more realistic and makes the choice 
task less abstract.32 Therefore, patients’ preferences, may be 
influenced not only by the processes of care (eg, treatment 
frequency) or benefits (eg, side effects), but also by the way 
the information is presented to patients.33
Further, our findings showed that sociodemographic, 
treatment, and behavioral aspects of individual patients 
appear to be important in determining patient preferences for 
treatment attributes. In multivariate analysis, we found that 
younger patients and women preferred treatments with greater 
likelihood of benefit, while older patients appeared more 
concerned with treatment side effects. A study by Gelfand 
et al reported that younger patients and women with psoriasis 
had greater impairment in quality of life as compared with 
men and older patients, potentially explaining why younger 
patients and women prefer treatments with greater likeli-
hood of benefit.34 We also found that patients with higher 
educational attainment least preferred prolonged inpatient 
treatment, possibly because greater education correlates with 
acquiring a position with higher earning potential, greater 
responsibility,35 and therefore busier schedules that would 
limit the ability to devote blocks of time to treatment.
Findings from previous studies have shown that smoking is 
significantly associated with increased psoriasis severity, and 
heavy and long-term smokers are more likely to have severe 
psoriasis,36,37 potentially explaining why patients still smoking 
in our sample appeared to be more concerned with the prob-
ability of treatment benefit and reduction in psoriasis plaques. 
The correlations we observed between patient characteristics, 
treatment history, behavioral factors, and their treatment pref-
erences (Table 3) raise the possibility that patient “profiles” 
or patient preference subgroups may exist. Acknowledging 
these profiles, if present, may be useful as clinicians develop 
treatment recommendations to optimize adherence.
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To our knowledge, this is the first study to examine 
patients’ treatment preferences in terms of features they 
most and least prefer. However, there are studies that have 
examined preferences for treatment attributes. Similar to a 
study reporting that time to achieve moderate improvement 
was rated higher than time to relapse,13 our results suggest 
strong patient preferences for treatment with high (100%) 
probability of benefit as compared with a long (6–8-month) 
duration of benefit (or time to relapse). These findings may 
indicate that patients are more concerned with the onset than 
the duration of treatment benefit. Further, in our previous 
study, location of treatment was the most important treatment 
attribute.12 From our current results, we may interpret this 
prior finding as arising from patients’ strong disutility for 
inpatient treatment associated with hospital stays of 3 weeks. 
Strong preferences for the location of treatment, in particular, 
suggest that patients are concerned and have opinions about 
the experience of   treatment beyond its ultimate outcomes. 
This conclusion is also supported by other studies that have 
used conjoint analysis in the health care setting to assess the 
value of process versus outcomes of treatments.12,38
The findings presented here justify further research. When 
examining patient preferences, future preference elicitation 
studies should consider both preferences for most and least 
preferred treatment options or attributes. A focus solely 
on aspects of treatment that a patient prefers may provide 
incomplete information on forces that influence treatment 
choice and adherence.
Strengths and limitations
We used choice-based conjoint analysis to measure patient 
preferences for psoriasis treatment attributes, a method 
considered to represent best the way people make everyday 
choices and which is easy to use and efficient in assessing 
patient preferences.18 Moreover, the hierarchical Bayes 
method we used to estimate individual-level preference 
scores is said to improve the reliability and predictive validity 
of individual preference models because the method borrows 
Table 3 Multiple regression analyses examining correlates of most and least preferred treatment attribute levels
Correlates Most preferred attribute levels Least preferred attribute levels
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
β P β P β  P β P β P β P


























  Age, years −0.134 0.021 0.112 0.259 0.157 0.044 0.051 0.624 −0.225 0.030 −0.035 0.047


























  Divorce, widowed, separated 0.107 0.025 0.141 0.010 0.041 0.664 −0.063 0.495 0.035 0.699 0.104 0.028
Education (referent, #11 years) 

























 . 15 years −0.020 0.835 −0.131 0.144 0.043 0.016 0.060 0.022 0.019 0.839 0.177 0.860
Monthly household income (referent, ,€1500)
  €1500–3000 −0.004 0.970 −0.004 0.967 −0.107 0.290 0.158 0.110 −0.018 0.853 0.035 0.707
 . €3000 −0.044 0.647 0.198 0.031 −0.066 0.507 0.044 0.050 0.016 0.862 −0.169 0.064
Current therapy (referent, other therapy)
  Topical 0.060 0.019 −0.121 0.157 0.093 0.315 0.105 0.029 −0.078 0.381 0.108 0.205
  Light −0.092 0.296 0.049 0.550 0.138 0.025 −0.071 0.417 −0.025 0.771 −0.153 0.041
  Tablets 0.069 0.432 −0.175 0.035 −0.082 0.363 −0.200 0.022 0.015 0.862 0.181 0.030
  Injection 0.068 0.048 0.024 0.793 −0.092 0.350 0.015 0.870 0.158 0.049 −0.003 0.983
Comorbidities (referent, other comorbidity)
  Psoriatic arthritis 0.004 0.078 −0.044 0.215 0.022 0.062 0.009 0.940 −0.031 0.270 −0.043 0.061
  Diabetes −0.003 0.971 −0.060 0.481 −0.042 0.630 0.007 0.992 0.005 0.958 −0.022 0.794
  Cardiovascular 0.087 0.361 −0.042 0.641 0.046 0.636 −0.078 0.409 −0.150 0.110 0.051 0.567
  Depression −0.016 0.855 −0.183 0.026 0.042 0.630 0.136 0.112 0.008 0.925 0.131 0.107
Smoking status (referent, still smoking)
  Smoked before −0.137 0.006 −0.205 0.036 0.034 0.744 0.143 0.161 0.171 0.070 0.174 0.062
  Never smoked −0.120 0.024 −0.225 0.017 0.114 0.260 0.048 0.621 0.137 0.182 0.240 0.054
Notes: Model 1, high (100%) probability of beneficial effects from treatment; model 2, high (100%) magnitude of beneficial effects from treatment; model 3, lower (1%) 
probability of side effects from treatment; model 4, treatment in hospital for 3 weeks; model 5, lower (40%) probability of beneficial effects from treatment; model 6, lower 
(25%) magnitude of beneficial effects from treatment; the bold text shows alpha values , 0.05.
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information from other respondents in the sample to stabilize 
estimates for each individual.26
However, it is important to note that, in preference 
elicitation, simplifications are made to make the exercises 
feasible. In conjoint analysis we assume, for example, that the 
utility functions attributable to respondents are additive and 
preferences for attribute levels are independent. However, 
preferences for attribute levels may not be independent in all 
cases.18 Further, although it is a strength of our study that we 
accounted for individual characteristics in our multivariable 
models, there might be individual differences even within 
these subgroups that are not captured by the rather broad 
categories we used. Therefore, treatment recommendations 
may need to be individualized to an even greater extent than 
suggested by our reference to patient profiles or preference 
subgroups. It may also be considered a limitation of this study 
that treatment attributes and attribute levels were specified 
without input from the patients. However, during the pilot 
phase of the study, feedback from the patients was used to 
refine and improve the comprehensiveness and clarity of the 
identified features of psoriasis treatment. Finally, our study 
sample included only patients with moderate-to-severe pso-
riasis, and the treatments they were offered may have differed 
from those offered to patients with mild psoriasis. Therefore, 
the generalizability of the study sample is limited.
Conclusion
Patients with psoriasis have preferences about the treatments 
they receive that are both strongly negative and strongly 
positive. To improve the effectiveness of psoriasis treatment, 
physicians deciding on which treatment to recommend should 
not only heed the best available evidence, but may also want 
to consider explicitly the utility and disutility patients attach 
to processes and outcomes of treatment for psoriasis.
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